ADMA BIOLOGICS, INC.
Close on Oct 19, 2026
- Market cap
- $2.55B
- P/E (TTM)
- 15.8
- Dividend yield
- –
About Adma Biologics
Biological Products, (No Diagnostic Substances), SIC 2836
ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics. It operates through two segments: ADMA BioManufacturing and Plasma Collection Centers. Its commercial therapies include ASCENIV and BIVIGAM, which treat primary humoral immunodeficiency, and Nabi-HB for hepatitis B exposure. The company also offers contract manufacturing and laboratory services. Its products serve physician specialists, hospitals, home infusion providers, and clinics treating immune-compromised patients, while collected plasma is also distributed to third-party manufacturers.
Headquartered in Ramsey, New Jersey, ADMA operates a plasma fractionation and purification facility in Boca Raton, Florida, capable of processing up to 600,000 liters annually. The company also maintains source plasma collection centers across the United States. Beyond domestic operations, several collection centers maintain regulatory approvals from South Korea's Ministry of Food and Drug Safety, and ADMA supplies plasma and products to customers in the United States and select international markets.
Summary of the business section of Adma Biologics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ADMA BIOLOGICS, INC.
- Headquarters
- Ramsey, NJ
- Address
- C/O Adma Biologics, Inc., 465 State Route 17 07446
- Phone
- (201) 478-5552
- Website
- www.admabiologics.com
- Employees
- 647, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Stamford, Connecticut
Stock & identifiers
- Ticker
- ADMA
- Exchange
- Nasdaq
- Shares outstanding
- 224M, Jul 31, 2026
- Public float
- $4.23B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1368514
- CUSIP
- 000899104
- ISIN
- US0008991046
- EIN
- 56-2590442
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Adam S. Grossman | President and CEO, Director | 2,699,734 |
| Kaitlin M. Kestenberg-Messina | COO and SVP, Compliance | 443,061 |
| Terry Kohler | CFO and Treasurer | 143,149 |
| Brad L. Tade | CFO and Treasurer | 232,940 |
| Jerrold B. Grossman | Director | 543,141 |
| Lawrence P. Guiheen | Director | 186,510 |
| Steve Elms | Director | 2,143,750 |
| Young Kwon | Director | 263,020 |
| Alison Cecily Finger | Director | 45,619 |
| Eduardo Rene Salas | Director | 21,579 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr.Adam Grossman | $10.24M | $13.62M | $2.87M | $106 | $126 |
| FY2024 Mr.Adam Grossman | $7.92M | $47.36M | $2.32M | $379 | $103 |
| FY2023 Mr.Adam Grossman | $6.04M | $14.08M | $1.97M | $116 | $130 |
| FY2022 Mr.Adam Grossman | $2.65M | $8.54M | $1.60M | $275 | $94 |
| FY2021 Mr.Adam Grossman | $4.36M | $2.00M | $1.73M | $72 | $123 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 647 employees, seven of whom are part-time.”
Corporate history
Events identified from SEC filings